DK3630772T3 - Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere - Google Patents

Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere Download PDF

Info

Publication number
DK3630772T3
DK3630772T3 DK18805780.6T DK18805780T DK3630772T3 DK 3630772 T3 DK3630772 T3 DK 3630772T3 DK 18805780 T DK18805780 T DK 18805780T DK 3630772 T3 DK3630772 T3 DK 3630772T3
Authority
DK
Denmark
Prior art keywords
making
methods
pde9 inhibitors
pde9
inhibitors
Prior art date
Application number
DK18805780.6T
Other languages
English (en)
Inventor
Niels Svenstrup
Jun Zhang
Jikui Sun
Yuyin Chen
Jianshe Kong
Rujian Ma
Junhua Zhang
Liang Qin
Huanming Xiao
Jinxu Sun
Xiao Meng
Fenglai Sun
Jingyang Zhu
Original Assignee
Cardurion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Inc filed Critical Cardurion Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3630772T3 publication Critical patent/DK3630772T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
DK18805780.6T 2017-05-26 2018-05-25 Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere DK3630772T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511367P 2017-05-26 2017-05-26
PCT/US2018/034566 WO2018218104A1 (en) 2017-05-26 2018-05-25 Methods of making and using pde9 inhibitors

Publications (1)

Publication Number Publication Date
DK3630772T3 true DK3630772T3 (da) 2024-02-05

Family

ID=64396048

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18805780.6T DK3630772T3 (da) 2017-05-26 2018-05-25 Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere

Country Status (19)

Country Link
US (2) US11370795B2 (da)
EP (1) EP3630772B1 (da)
JP (1) JP2020527535A (da)
KR (1) KR102627975B1 (da)
CN (2) CN111183140B (da)
BR (1) BR112019024877A2 (da)
CA (1) CA3064004A1 (da)
DK (1) DK3630772T3 (da)
EA (1) EA201992721A1 (da)
FI (1) FI3630772T3 (da)
HR (1) HRP20240146T1 (da)
IL (1) IL270792B2 (da)
LT (1) LT3630772T (da)
MA (1) MA48793A (da)
MX (2) MX2019014049A (da)
PT (1) PT3630772T (da)
RS (1) RS65143B1 (da)
TW (2) TWI791021B (da)
WO (1) WO2018218104A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3303339T3 (da) 2015-07-07 2021-04-12 H Lundbeck As Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
WO2018218104A1 (en) 2017-05-26 2018-11-29 Imara, Inc. Methods of making and using pde9 inhibitors
CN109734653B (zh) * 2019-02-21 2020-07-14 北京悦康科创医药科技股份有限公司 一种阿加曲班起始原料异构体杂质的拆分方法
WO2020202183A1 (en) * 2019-03-29 2020-10-08 Mylan Laboratories Limited The process for the preparation of upadacitinib and its intermediates
CA3136128A1 (en) * 2019-04-05 2020-10-08 Imara Inc. Pde9 inhibitors for treating sickle cell disease
WO2022036111A1 (en) * 2020-08-13 2022-02-17 Imara Inc. Methods and compositions for treating sickle cell disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9508554A (pt) 1994-08-08 1997-11-25 Debiopharm Sa Preparação farmaceuticamente estável de oxaliplatina
DK1368022T3 (da) 2001-03-02 2007-10-01 Debiopharm Sa Anvendelse af en flaske indeholdende en oxaliplatinoplösning
IL161155A0 (en) * 2001-11-02 2004-08-31 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
WO2004037311A2 (en) 2002-10-21 2004-05-06 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
EP2152712B1 (en) * 2007-05-11 2012-01-11 Pfizer Inc. Amino-heterocyclic compounds
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
EP2619208B1 (en) 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
MX370433B (es) * 2011-10-10 2019-12-13 H Lundbeck As Derivados de 7h-imidazo [1-5-a] pirazin-8-ona como inhibidores de la fosfodiasterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos.
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
DK2890384T3 (da) 2012-08-31 2022-01-10 Taris Biomedical Llc Lægemiddelleveringsystemer og fremgangsmåder til behandling af blærekræft omfattende oxaliplatin
US9301926B2 (en) 2013-04-10 2016-04-05 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
DK3303339T3 (da) 2015-07-07 2021-04-12 H Lundbeck As Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
WO2018218104A1 (en) 2017-05-26 2018-11-29 Imara, Inc. Methods of making and using pde9 inhibitors

Also Published As

Publication number Publication date
CN111183140B (zh) 2022-12-02
MX2023000191A (es) 2023-02-09
IL270792A (en) 2020-01-30
CA3064004A1 (en) 2018-11-29
KR102627975B1 (ko) 2024-01-19
LT3630772T (lt) 2024-02-26
HRP20240146T1 (hr) 2024-04-12
RS65143B1 (sr) 2024-02-29
BR112019024877A2 (pt) 2020-06-09
JP2020527535A (ja) 2020-09-10
WO2018218104A1 (en) 2018-11-29
EP3630772A1 (en) 2020-04-08
PT3630772T (pt) 2024-02-05
US11370795B2 (en) 2022-06-28
MA48793A (fr) 2020-04-08
CN111183140A (zh) 2020-05-19
TWI791021B (zh) 2023-02-01
EP3630772B1 (en) 2023-11-01
US20200157108A1 (en) 2020-05-21
EP3630772A4 (en) 2021-01-13
MX2019014049A (es) 2020-07-28
TW202334156A (zh) 2023-09-01
US20230183244A1 (en) 2023-06-15
TW201908319A (zh) 2019-03-01
IL270792B1 (en) 2023-09-01
FI3630772T3 (fi) 2024-01-31
CN115746003A (zh) 2023-03-07
KR20200016891A (ko) 2020-02-17
IL270792B2 (en) 2024-01-01
EA201992721A1 (ru) 2020-09-10

Similar Documents

Publication Publication Date Title
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3630761T3 (da) Kras-g12c-inhibitorer og fremgangsmåder til anvendelse af disse
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3551660T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3430378T3 (da) Indretninger og fremgangsmåder til modifikation af optiske egenskaber
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3529257T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3350201T3 (da) Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3474996T3 (da) Tågeapparat og anvendelsesmåde
DK3630772T3 (da) Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere
DK3227310T3 (da) Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
DK3250610T3 (da) Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3551209T3 (da) Insulin-fc-fusioner og fremgangsmåder til anvendelse
DK3368578T3 (da) Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf
DK3574135T3 (da) Fremgangsmåde og formulering til fremstilling af ligninfibre
DK3447051T3 (da) Fremgangsmåde til fremstilling af tyrosinkinaseinhibitor og derivat deraf
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3277742T3 (da) Fluorescerende siloxanelastomer, fremgangsmåde til fremstilling af denne og anvendelsen
DK3072560T3 (da) Trampolinsystemer og fremgangsmåder til fremstilling og anvendelse deraf